RxDoctor Payments Data

Avesh Verma, MD

Neurology · Plano, TXNPI 1558563031

Payments from drug & device makers

$7,787in general payments, 2019–2025

Across 323 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$899
  • MDD US Operations, LLC$663
  • SK Life Science, Inc.$480
  • UCB, Inc.$362
  • Lilly USA, LLC$341
  • Biogen$284
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$7,787100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)56$899
MDD US Operations, LLC14$663
SK Life Science, Inc.15$480
UCB, Inc.12$362
Lilly USA, LLC16$341
Biogen12$284
Genentech USA, Inc.10$251
Novartis7$190
Teva Pharmaceuticals USA, Inc.6$187
Microtransponder, Inc.1$184
Argenx US, Inc.6$163
Pfizer8$154
Sanofi6$139
Neurocrine Biosciences, Inc.6$136
EMD Serono, Inc.4$132
Jazz Pharmaceuticals Inc.5$131
Lundbeck LLC5$125
Grifols USA, LLC6$125
AstraZeneca(2 entities)6$123
Eisai Inc.4$119
Johnson & Johnson(2 entities)5$116
Upsher-smith Laboratories LLC5$111
Boston Scientific4$108
GE HealthCare5$105
Kyowa Kirin, Inc.4$98
Amgen4$97
Mallinckrodt Hospital Products Inc.5$96
Axsome Therapeutics, Inc.3$90
Merz Pharmaceuticals, LLC3$88
Scilex Pharmaceuticals Inc.5$88
Amneal Pharmaceuticals LLC4$85
ANI Pharmaceuticals, Inc.3$80
Abbott4$79
Sumitomo Pharma America, Inc.5$79
Siemens Medical Solutions USA, Inc.1$78
Biohaven Pharmaceuticals, Inc.4$70
Impel Pharmaceuticals Inc.3$68
Otsuka America Pharmaceutical, Inc.3$65
Tanabe Pharma America, Inc.3$63
Bristol Myers Squibb3$58
Corium, LLC4$58
CSL Behring2$57
Azurity Pharmaceuticals, Inc.3$57
Biohaven Pharmaceutical Holding Company Ltd.3$53
Acorda Therapeutics, Inc2$50
Takeda Pharmaceuticals U.S.A., Inc.2$50
Sunovion Pharmaceuticals Inc.2$45
Harmony Biosciences LLC2$41
E.r. Squibb & Sons, L.L.C.2$40
Avadel CNS Pharmaceuticals, LLC2$39
Avion Pharmaceuticals2$37
Collegium Pharmaceutical, Inc.2$36
ZOLL Respicardia, Inc.1$35
Averitas Pharma Inc.1$32
TG Therapeutics, Inc.1$30
Avanir Pharmaceuticals, Inc.2$27
Aprecia Pharmaceuticals, LLC1$25
Merck1$25
Neurelis, Inc.1$24
Aucta Pharmaceuticals, Inc.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,787 in reported general payments places this provider in the 60th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$280,851
Medicare patients
788
Services billed
15,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4644$264,303
Aimovig AutoinjectorErenumab-Aooe85$73,660
Glatiramer Acetate19$32,364
UbrelvyUbrogepant27$25,822
RytaryCarbidopa/Levodopa17$23,529
Nurtec OdtRimegepant Sulfate12$21,956
Lacosamide89$15,587
NeuproRotigotine13$13,992
EliquisApixaban11$10,550
XareltoRivaroxaban11$9,146
Memantine Hcl186$8,603
KeppraLevetiracetam11$8,591
Emgality PenGalcanezumab-Gnlm12$8,197
LamictalLamotrigine12$7,996
Gabapentin307$6,844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$125$264,30344 claims
PfizerNurtec Odt, Eliquis$154$32,50623 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$85$27,38641 claims
AbbVieUbrelvy$899$25,82227 claims
UCB, Inc.Neupro$362$13,99213 claims
Johnson & JohnsonXarelto$116$9,14611 claims
Upsher-smith Laboratories LLCTopiramate$111$2,118146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,246 neurology providers in Texas.

Other neurology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →